Latest Biotech News

Researchers reported new retron‑based gene‑editing technologies that use bacterial retrons to produce multicopy single‑stranded DNA templates inside cells, enabling precise replacement and...

High‑resolution, light‑sheet live imaging of late‑stage human preimplantation embryos revealed de novo mitotic errors in trophectoderm cells that were not detectable at earlier stages, challenging...

Flagship Pioneering launched Expedition Medicines with a $50 million commitment to develop covalent‑binding small molecules using generative AI, quantum chemistry and chemoproteomics. The new...

Qureator announced that the FDA approved an Investigational New Drug (IND) application based solely on efficacy data generated with its vascularized tumor organoid model (vTIME), marking the first...

Takeda agreed to a major licensing and co‑development transaction with Innovent Biologics that includes $1.2 billion in up‑front payments and potential total consideration up to $11.4 billion for...

Ventyx Biosciences reported Phase 2 data showing its oral NLRP3 inhibitor VTX‑3232 produced rapid, large reductions in inflammatory biomarkers linked to cardiovascular risk. In a randomized,...

Moderna announced that its Phase III CMV vaccine, mRNA‑1647, missed the primary efficacy endpoint and the company will stop further development of the shot for most populations. The pivotal...

Alector disclosed that its GSK‑partnered antibody failed to meet co‑primary clinical endpoints in a Phase III dementia trial. The negative outcome prompted the company to stop development of the...

Takeda struck a landmark partnership to license up to three immuno‑oncology and ADC candidates from Innovent Biologics in a deal valued at $11.4 billion, including a $1.2 billion up‑front payment....

Regeneron ended clinical development of bbT369, a dual‑targeting CAR‑T acquired with 2seventy bio, and halted enrollment in the dose‑escalation lymphoma study before advancing to phase 2. The...

10x Genomics joined Roche Sequencing Solutions and Prognosys Biosciences to file two federal lawsuits accusing Illumina of infringing nine patents tied to spatial transcriptomics and single‑cell...

Flagship Pioneering unveiled Expedition Medicines with a $50 million commitment to develop covalent‑binding small molecules using generative chemistry, quantum‑informed models and chemoproteomics....

Qureator and partner SillaJen secured an FDA IND that relied solely on efficacy data generated from human vascularized tumor organoid models (vTIME), marking the first U.S. oncology IND cleared...

Roche reported diagnostics revenues down 4% year‑to‑date and told investors that China's volume‑based procurement and diagnostic‑related group audits materially hit pricing and volumes in 2025....

Electra Therapeutics closed a $183 million Series C to fund pivotal testing of its lead monoclonal antibody ELA026 for secondary hemophagocytic lymphohistiocytosis (HLH) and to advance additional...

Merck KGaA announced it will wind down active pharmaceutical ingredient (API) production at its Arklow, Ireland site and proposed closing the factory at the end of 2028, the company told Endpoints...

Alector said a GSK-partnered antibody failed a pivotal Phase III study and the company will cut roughly half its staff as it ends development of that asset. The Bay Area biotech also announced...

Moderna reported that its cytomegalovirus (CMV) vaccine failed to meet its primary efficacy endpoint in a large Phase III trial and said it will stop most development of the program. The...

Ventyx Biosciences reported Phase 2 data showing its oral NLRP3 inhibitor VTX3232 produced a dramatic 78% reduction in high-sensitivity C‑reactive protein (hsCRP) over 12 weeks as a monotherapy,...

Flagship Pioneering launched Expedition Medicines with a $50 million commitment to build an AI-driven platform focused on covalent small-molecule drug discovery, the firm said. Expedition emerges...